Expression of Erythroid Differentiation Regulator 1 (Erdr1) in Vitiligo
Sponsor
Cairo University (Other)
Overall Status
Unknown status
CT.gov ID
NCT03377998
Collaborator
(none)
100
2
5.9
Study Details
Study Description
Brief Summary
Expression of Erythroid differentiation regulator 1 (Erdr1) cytokine in vitiligo
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Study Design
Study Type:
Interventional
Anticipated Enrollment
:
100 participants
Allocation:
Non-Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Health Services Research
Official Title:
Expression of Erythroid Differentiation Regulator 1 (Erdr1) Cytokine in the Vitiliginous Skin Lesions: a Case Control Study
Anticipated Study Start Date
:
Jan 1, 2018
Anticipated Primary Completion Date
:
Jul 1, 2018
Anticipated Study Completion Date
:
Jul 1, 2018
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: vitiligo patients lesional skin biopsy to measure ERDR1 level |
Other: skin biopsy
Skin biopsy for measuring tissue levels of the Erythroid differentiation regulator 1 (Erdr1) cytokine will be taken from the lesional skin of patients of vitiligo and from normal skin of healthy controls.
|
| Experimental: controls normal skin biopsy to measure ERDR1 level |
Other: skin biopsy
Skin biopsy for measuring tissue levels of the Erythroid differentiation regulator 1 (Erdr1) cytokine will be taken from the lesional skin of patients of vitiligo and from normal skin of healthy controls.
|
Outcome Measures
Primary Outcome Measures
- Expression of tissue levels of erythroid differentiation regulator 1 (Erdr1) cytokine in patients of vitiligo [6 months]
Expression of tissue levels of erythroid differentiation regulator 1 (Erdr1) cytokine in patients of vitiligo and comparing its level in normal subjects
Eligibility Criteria
Criteria
Ages Eligible for Study:
18 Years
and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
-
Patients with generalized non-segmental vitiligo.
-
Both sexes.
-
Age >18 years old.
-
New cases or cases not receiving any medication for at least 3 months ago.
Exclusion Criteria:
-
Segmental or Universal vitiligo
-
Autoimmune diseases
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Cairo University
Investigators
- Principal Investigator: Maha Elmasry, MD, Cairo University
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
Maha Fathy Elmasry,
principal investigator,
Cairo University
ClinicalTrials.gov Identifier:
NCT03377998
Other Study ID Numbers:
- Dermatology 4
First Posted:
Dec 19, 2017
Last Update Posted:
Dec 19, 2017
Last Verified:
Dec 1, 2017
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No